Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.

Ranbaxy loses Valcyte exclusivity: An analysis

Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.

Expect revenue of around Rs 400 cr in Q4: Shasun Pharma

Abhaya Kumar of Shasun Pharma believes Q4 is always a better quarter and hopes to maintain revenue growth and EBITDA at around current levels.

To clock Rs 1500cr in revenues for 2013-14: Shasun Pharma

Shasun Pharmaceuticals has big capacity expansion plans for 2013-14. Speaking to CNBC-TV18, managing director Abhaya Kumar says the company is planning an investment of more than Rs 250 crore towards achieving this aim.

Sun Pharma to continue holding stake in Taro, says VP Fin

Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma said the company will continue to hold stake in Taro despite their termination of the merger agreement.

Shasun Pharma eyes robust Q4 growth, says MD

Abhaya Kumar, MD of Shasun Pharmaceuticals said the Q3 margins were stressed owing to price pressures from the US.

UK biz strong; see FY13 revenue at Rs 1,200cr: Shashun

Shasun Pharma is one of the key suppliers to Vertex for Hepatitis C drug -Incivek, which has received a US Food & Drug Administration (USFDA) 'Black Box' warning. This warning indicates that if one gets severe rash symptoms then the drug should be stopped using immediately.

Capacity debottlenecking led to growth: Shasun Pharma

Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.

Shasun Pharma plans Rs 250cr expansion

In an interview to CNBC-TV18, Abhaya Kumar, managing director of Shasun Pharmaceuticals says, the company has huge expansion plans. “Shasun is on a very high expansion spree now, investing more than Rs 250 crore in Vizag and in other places. We have raised Rs 50 crore,” he adds.

Growth in margins sustainable going forward: Shasun Pharma

Abhaya Kumar, managing director of Shasun Pharmaceuticals, tells CNBC-TV18 that the jump in margins is sustainable going ahead.

Shasun Pharma expects 40-50% topline growth in FY12

Abhaya Kumar, managing director of Shasun Pharmaceuticals expects the company's topline to grow 40-50% in FY12. He told CNBC-TV18 in an interview that their confirmed orders for third and fourth quarter are very strong.

Merck JV will earn revenues in a few years, says Sun Pharma

In an exclusive interview with CNBC-TV18, Uday Baldota of Sun Pharma says the company saw significant growth in Sun Pharma’s standalone numbers, while as well "Taro reported strong margins this quarter." The leading drugmaker discloses that the company is "bearing additional costs for some non-revenue generating businesses."

Shasun Chem to launch 'Hepatitis C' in June-July 2012

The supply on the Hepatitis C drug to Vertex by Shasun Chemicals is set to take off earlier than anticipated. "Commercial supplies have already started and this year we are preparing for the launch," says Vimal Kumar, Managing Director of Shasun Chemicals, in an exclusive interview with CNBC-TV18.